- Indications for Kadcyla
- Kadcyla price
- How to use Kadcyla
- Side effects of Kadcyla
- Contraindications for Kadcyla
Kadcyla is a drug indicated for the treatment of breast cancer with several metatheses in the body. This medicine works by preventing the growth and formation of new cancer cell metastases.
Kadcyla is a drug produced by the pharmaceutical company Roche.
Indications for Kadcyla
Kadcyla is indicated for the treatment of breast cancer already in an advanced stage and already spread to other parts of the body. It is usually given to the patient after other cancer drugs have been given and have not been successful.
The drug Kadcyla consists of two drugs, trastuzumab that prevents the growth of cancer cells and the mertansine that enters the cells and destroys them, reducing the tumor and the progress of the disease, as well as prolonging the patient's life.
Kadcyla price
The price of Kadcyla per month is $ 9800, with a 9.6-month course of treatment costing $ 94, 000.
How to use Kadcyla
The recommended dose of Kadcyla is 3.6 mg / kg and is administered by intravenous injection every 3 weeks.
In the first treatment, the drug should be administered for 90 minutes, with the patients being observed for the appearance of side effects. If well tolerated, the drug should be administered for at least 30 minutes.
Doses greater than 3.6 mg / kg should not be administered.
Side effects of Kadcyla
The side effects of Kadcyla are:
- Fatigue; Nausea and vomiting: Muscle pain; Reduction in the number of platelets in the blood; Headache; Increased liver transaminases; Constipation.
Contraindications for Kadcyla
Kadcyla is contraindicated during pregnancy because it causes serious and life-threatening genetic problems for the baby.
Some medicines may interact with Kadcyla as
- Imatinib; Isoniazid; Clarithromycin and telithromycin; Antifungal drugs; Medicines for the heart: nicardipine, quinidine; Medicines for hepatitis C: boceprevir, telaprevir; AIDS medications; Vitamins and natural products.
The doctor should always be informed of the medications the patient uses regularly or is taking at the time he starts treatment.
